<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Eur J Hum Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Eur. J. Hum. Genet</journal-id>
<journal-title-group>
<journal-title>European Journal of Human Genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1018-4813</issn>
<issn pub-type="epub">1476-5438</issn>
<publisher>
<publisher-name>Springer International Publishing</publisher-name>
<publisher-loc>Cham</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31053780</article-id>
<article-id pub-id-type="pmc">6777539</article-id>
<article-id pub-id-type="publisher-id">418</article-id>
<article-id pub-id-type="doi">10.1038/s41431-019-0418-1</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A novel de novo <italic>MTOR</italic> gain-of-function variant in a patient with Smith-Kingsmore syndrome and Antiphospholipid syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Rodríguez-García</surname>
<given-names>María Elena</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Cotrina-Vinagre</surname>
<given-names>Francisco Javier</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Bellusci</surname>
<given-names>Marcello</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martínez de Aragón</surname>
<given-names>Ana</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hernández-Sánchez</surname>
<given-names>Laura</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carnicero-Rodríguez</surname>
<given-names>Patricia</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martín-Hernández</surname>
<given-names>Elena</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6250-7745</contrib-id>
<name>
<surname>Martínez-Azorín</surname>
<given-names>Francisco</given-names>
</name>
<address>
<phone>+34 91 779 2784</phone>
<email>fmartinez@h12o.es</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1945 5329</institution-id><institution-id institution-id-type="GRID">grid.144756.5</institution-id><institution>Laboratorio de Enfermedades Mitocondriales. Instituto de Investigación Hospital 12 de Octubre (i+12), </institution></institution-wrap>E-28041 Madrid, Spain </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1945 5329</institution-id><institution-id institution-id-type="GRID">grid.144756.5</institution-id><institution>Unidad Pediátrica de Enfermedades Raras, Enfermedades Mitocondriales y Metabólicas Hereditarias, Hospital 12 de Octubre, </institution></institution-wrap>E-28041 Madrid, Spain </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1945 5329</institution-id><institution-id institution-id-type="GRID">grid.144756.5</institution-id><institution>Unidad Pediátrica de Neurorradiología, Hospital 12 de Octubre, </institution></institution-wrap>E-28041 Madrid, Spain </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1791 1185</institution-id><institution-id institution-id-type="GRID">grid.452372.5</institution-id><institution>Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, </institution></institution-wrap>E-28041 Madrid, Spain </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>3</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>9</month>
<year>2019</year>
</pub-date>
<volume>27</volume>
<issue>9</issue>
<fpage>1369</fpage>
<lpage>1378</lpage>
<history>
<date date-type="received">
<day>22</day>
<month>11</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>21</day>
<month>3</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>4</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© European Society of Human Genetics 2019</copyright-statement>
</permissions>
<abstract id="Abs1">
<p id="Par1">We report the clinical, biochemical and genetic findings from a Spanish girl of Caucasian origin who presented with macrocephaly, dysmorphic facial features, developmental delay, hypotonia, combined oxidative phosphorylation (OxPhos) deficiency, epilepsy and anti-phospholipid antibodies (aPL). Whole-exome sequencing (WES) uncovered a heterozygous variant in the <italic>MTOR</italic> gene (NM_004958.3: c.7235A&gt;T: p.(Asp2412Val)) that encodes for the Serine/threonine-protein kinase mTOR. The substrates phosphorylation experiments demonstrated that this variant exerts its effect by gain-of-function (GOF) and autosomal dominant mechanism. GOF variants in this protein have been associated with Smith-Kingsmore syndrome (SKS), a rare autosomal dominant disorder characterized by intellectual disability, macrocephaly, seizure, developmental delay and dysmorphic facial features. Furthermore, the mTOR pathway has been demonstrated previously to be involved in many types of endothelium injuries including the antiphospholipid syndrome (APS), a systemic autoimmune disease characterized by the production of aPL with recurrent vascular thrombosis. Therefore, our patient is the first one with an mTOR variant and diagnosed with SKS and APS. In conclusion, our data expand both the genetic and phenotypic spectrum associated with <italic>MTOR</italic> gene variants.</p>
</abstract>
<kwd-group kwd-group-type="npg-subject">
<title>Subject terms</title>
<kwd>Paediatric neurological disorders</kwd>
<kwd>Autoimmune diseases</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s), under exclusive licence to European Society of Human Genetics 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>